XRCC1 polymorphisms and severe toxicity in lung cancer patients treated with cisplatin-based chemotherapy in Chinese population

Lung Cancer

Volumn 62, Issue 1, 2008, Pages 99-104

  Wang, Zhonghua ^a   Xu, Binghe ^b   Lin, Dongxin ^b   Tan, Wen ^b   Leaw, Shiangjiin ^a   Hong, Xiaonan ^a   Hu, Xichun ^a  

^a FUDAN UNIVERSITY   (China)

^b CANCER HOSPITAL   (China)

Author keywords

Chemotherapy; Lung cancer; Polymorphisms; Toxicity; XRCC1

Indexed keywords

CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; NAVELBINE; PACLITAXEL; XRCC1 PROTEIN;

ADULT; AGED; ALLELE; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; DIARRHEA; FEBRILE NEUTROPENIA; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CISPLATIN; DNA-BINDING PROTEINS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 52149093686     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.02.019     Document Type: Article

References (31)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. Mountain C. Revisions in the International System for Staging Lung Cancer. Chest 111 (1997) 1710-1717
3. Proceedings of the European Consensus Conference on Medical Treatment of Non-small Lung Cancer. Lung Cancer 2002;38(suppl 3):S1-85.
4. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized trials. BMJ 311 (1995) 899-909
5. Simon G.R., and Wagner H. Small cell lung cancer. Chest 123 (2003) 259S-271S
6. Silvestri G., Pritchard R., and Welch H.G. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ 317 (1998) 771-775
7. Berkun Y., Levartovsky D., Rubinow A., Orbach H., Aamar S., Grenader T., et al. Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene. Ann Rheum Dis 63 (2004) 1227-1231
8. Innocenti F., Undevia S.D., Iyer L., Chen P.X., Das S., Kocherginsky M., et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22 (2004) 1382-1388
9. Yonemori K., Ueno H., Okusaka T., Yamamoto N., Ikeda M., Saijo N., et al. Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin Cancer Res 11 (2005) 2620-2624
10. Zienolddiny S., Campa D., Lind H., Ryberg D., Skaug V., Stangeland L., et al. Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis 27 (2006) 560-567
11. Xing D., Qi J., Miao X., Lu W., Tan W., and Lin D. Polymorphisms of DNA repair genes XRCC1 and XPD and their associations with risk of esophageal squamous cell carcinoma in a Chinese population. Int J Cancer 100 (2002) 600-605
12. Park J.Y., Lee S.Y., Jeon H.S., Bae N.C., Chae S.C., Joo S., et al. Polymorphism of the DNA repair gene XRCC1 and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev 11 (2002) 23-27
13. Hung R.J., Brennan P., Canzian F., Szeszenia-Dabrowska N., Zaridze D., Lissowska J., et al. Large-scale investigation of base excision repair genetic polymorphisms and lung cancer risk in a multicenter study. J Natl Cancer Inst 97 (2005) 567-576
14. Isla D., Sarries C., Rosell R., Alonso G., Alonso G., Domine M., et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 15 (2004) 1194-1203
15. Park D.J., Stoehlmacher J., Zhang W., Tsao-Wei D.D., Groshen S., and Lenz H.J. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 61 (2001) 8654-8658
16. de las Peñas R., Sanchez-Ronco M., Alberola V., Taron M., Camps C., Garcia-Carbonero R., et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 17 (2006) 668-675
17. Wei Q., Frazier M.L., and Levin B. DNA repair: a double-edged sword. J Natl Cancer Inst 92 (2000) 440-441
18. Rosell R., Lord R.V., Taron M., and Reguart N. DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer 38 (2002) 217-227
19. Lunn R.M., Langlois R.G., Hsieh L.L., Thompson C.L., and Bell D.A. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res 59 (1999) 2557-2561
20. El-Khamisy S.F., Masutani M., Suzuki H., and Caldecott K.W. A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Res 31 (2003) 5526-5533
21. Chen S., Tang D., Xue K., Xu L., Ma G., Hsu Y., et al. DNA repair gene XRCC1 and XPD polymorphisms and risk of lung cancer in a Chinese population. Carcinogenesis 23 (2002) 1321-1325
22. Zhang X., Miao X., Liang G., Hao B., Wang Y., Tan W., et al. Polymorphisms in DNA base excision repair genes ADPRT and XRCC1 and risk of lung cancer. Cancer Res 65 (2005) 722-726
23. Rybicki B.A., Conti D.V., Moreira A., Cicek M., Casey G., and Witte J.S. DNA repair gene XRCC1 and XPD polymorphisms and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 13 (2004) 23-29
24. Duell E.J., Millikan R.C., Pittman G.S., Winkel S., Lunn R.M., Tse C.K., et al. Polymorphisms in the DNA repair gene XRCC1 and breast cancer. Cancer Epidemiol Biomarkers Prev 10 (2001) 217-222
25. Cho E.Y., Hildesheim A., Chen C.J., Hsu M.M., Chen I.H., Mittl B.F., et al. Nasopharyngeal carcinoma and genetic polymorphisms of DNA repair enzymes XRCC1 and hOGG1. Cancer Epidemiol Biomarkers Prev 12 (2003) 1100-1104
26. Lee S.G., Kim B., Choi J., Kim C., Lee I., and Song K. Genetic polymorphisms of XRCC1 and risk of gastric cancer. Cancer Lett 187 (2002) 53-60
27. Patel A.V., Calle E.E., Pavluck A.L., Feigelson H.S., Thun M.J., and Rodriguez C. A prospective study of XRCC1 (X-ray cross-complementing group 1) polymorphisms and breast cancer risk. Breast Cancer Res 7 (2005) R1168-R1173
28. Wang Z.H., Miao X.P., Tan W., Zhang X.R., Xu B.H., and Lin D.X. Single nucleotide polymorphisms in XRCC1 and clinical response to platin-based chemotherapy in advanced non-small cell lung cancer. Ai Zheng 23 (2004) 865-868 [Article in Chinese]
29. Gurubhagavatula S., Liu G., Park S., Zhou W., Su L., Wain J.C., et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 22 (2004) 2594-2601
30. Stoehlmacher J., Ghaderi V., Iobal S., Groshen S., Tsao-Wei D., Park D., et al. A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res 21 (2001) 3075-3079
31. Ando Y., Saka H., Ando M., Sawa T., Muro K., Ueoka H., et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60 (2000) 6921-6926